ABCG2 and cancer: While further investigation is required to understand the mechanisms of acquired resistance in patients treated with furmonertinib, our results indicate that the overexpression of ABCB1 or ABCG2 is unlikely to play a significant role in the development of resistance to furmonertinib in cancer cells.